What question did this study set out to answer?

This report examines the use of bortezomib as a treatment for refractory pediatric autoimmune haemolytic anemia.

February 28, 2026Pediatric Hematology Oncology JournalOpen Access

“Bortezomib as Plasma Cell – Directed Therapy in Pediatric Refractory Autoimmune Haemolytic Anaemia: A Report of two cases ”

View Full Paper

Ask AI

Bookmark

Authors

KCKAG RAKESH CHOUDHARYJawaharlal Nehru Medical College SAS. ABHILASHAJawaharlal Nehru Medical College

Discussion

Member takes

Implication

Case report demonstrates improvement of hemoglobin levels in children with refractory autoimmune hemolytic anemia using bortezomib, highlighting its potential benefits.

Key Points

This report examines the use of bortezomib as a treatment for refractory pediatric autoimmune haemolytic anemia.
Case reports of a 6-year-old boy and a 10-year-old girl with chronic refractory autoimmune haemolytic anemia.
Initial treatments included corticosteroids and intravenous immunoglobulin, followed by Rituximab, MMF, and Azathioprine.
Both patients were treated with bortezomib after failing conventional therapies.
Both patients experienced significant hemoglobin improvement following bortezomib treatment.
The first case stabilized at 11 g/dL and the second at 10.6 g/dL after respective doses of 10 and 8.
Both have remained transfusion-independent for 3 months and 2 months, respectively.

Cite This Study

CHOUDHARY et al. (2026) studied this question.

synapsesocial.com/papers/69a286c90a974eb0d3c02099 https://doi.org/10.1016/j.phoj.2026.100812

View Full Paper

Ask AI

Bookmark

February 28, 2026Pediatric Hematology Oncology JournalOpen Access

“Bortezomib as Plasma Cell – Directed Therapy in Pediatric Refractory Autoimmune Haemolytic Anaemia: A Report of two cases ”

View Full Paper

Ask AI

Bookmark

Authors

KCKAG RAKESH CHOUDHARYJawaharlal Nehru Medical College SAS. ABHILASHAJawaharlal Nehru Medical College

Discussion

Member takes

Implication

Case report demonstrates improvement of hemoglobin levels in children with refractory autoimmune hemolytic anemia using bortezomib, highlighting its potential benefits.

Key Points

This report examines the use of bortezomib as a treatment for refractory pediatric autoimmune haemolytic anemia.
Case reports of a 6-year-old boy and a 10-year-old girl with chronic refractory autoimmune haemolytic anemia.
Initial treatments included corticosteroids and intravenous immunoglobulin, followed by Rituximab, MMF, and Azathioprine.
Both patients were treated with bortezomib after failing conventional therapies.
Both patients experienced significant hemoglobin improvement following bortezomib treatment.
The first case stabilized at 11 g/dL and the second at 10.6 g/dL after respective doses of 10 and 8.
Both have remained transfusion-independent for 3 months and 2 months, respectively.

Cite This Study

CHOUDHARY et al. (2026) studied this question.

synapsesocial.com/papers/69a286c90a974eb0d3c02099 https://doi.org/10.1016/j.phoj.2026.100812

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark